Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving β-hydroxy-β-methylglutaryl-coenzyme a reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol

Bulletin of Experimental Biology and Medicine

Volumn 134, Issue 1, 2002, Pages 39-42

  Lankin, V Z ^a   Tikhaze, A K ^a   Konovalova, G G ^a   Tutunov, V S ^a   Medvedeva, N V ^a   Kotkina, T I ^a   Kukharchuk, V V ^a   Belenkov, Yu N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Hydroxy methylglutaryl coenzyme A reductase inhibitors; Antioxidants; Cerivastatin; Free radical lipid oxidation; Hypercholesterolemia; Low density lipoproteins; Probucol; Ubiquinone Q10

Indexed keywords

ALCOLEX; ANTILIPEMIC AGENT; ANTIOXIDANT; CERIVASTATIN; CHOLESTEROL; FREE RADICAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; PROBUCOL; UBIDECARENONE;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG OXIDATION; DRUG POTENCY; DRUG USE; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL;

ANTIOXIDANTS; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FREE RADICALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OXYGEN; PEROXIDES; PLACEBOS; PROBUCOL; PYRIDINES; RANDOM ALLOCATION; TIME FACTORS; UBIQUINONE;

EID: 0036665004     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020652504303     Document Type: Article

References (15)

1. V. Z. Lankin, A. K. Tikhaze, and Yu. N. Belenkov, Kardiologiya, 40, No. 7, 48-61 (2000).
2. V. Z. Lankin, A. K. Tikhaze, V. I. Kaminnaya, et al., Byull. Eksp. Biol. Med., 129, No. 2, 176-179 (2000).
3. O. I. Pisarenko, I. M. Studneva, V. Z. Lankin, et al., Ibid., 130, No. 10, 401-403 (2001).
4. A. K. Tikhaze, V. Z. Lankin, G. G. Konovalova, et al., Ibid., 128, No. 8, 186-189 (1999).
5. A. K. Tikhaze, V. Z. Lankin, V. P. Mikhin, et al., Ter. Arkh., 59, No. 9, 35-41 (1997).
6. J. Davignon and R. Laaksonen, Curr. Opin. Lipidol., 10, 543-559 (1999).
7. C. A. Dujovne, Ibid., 8, No. 6, 362-368 (1997).
8. K. Folkers, P. Langsjoen, R. Willis, et al., Proc. Natl. Acad. Sci. USA, 87, 8931-8934 (1990).
9. F. T. Lindgren, Analysis of Lipids and Lipoproteins, New York (1975), pp. 204-224.
10. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, and S. R. Wolff, Anal. Biochem., 220, 403-409 (1994).
11. A. Palomaki, K. Malminiemi, and O. Malminiemi, Arterioscler. Thromb. Vasc. Biol., 19, 1541-1548 (1999).
12. A. Palomaki, K. Malminiemi, T. Solakivi, and O. Malminiemi, J. Lipid Res., 39, 1430-1437 (1998).
13. R. Stocker, V. W. Bowry, and B. Frei, Proc. Natl. Acad. Sci. USA, 88, 1646-1650 (1991).
14. A. Szczeklik, R. J. Gryglewski, B. Domagala, et al., Prostaglandins, 22, 795-807 (1981).
15. V. V. Tertov, V. V. Kaplun, S. N. Dvoryantsev, et al., Biochem. Biophys. Res. Commun., 214, 608-613 (1995).